Iconocast Logo

Welcome To Iconocast

How to add a URL link from your web site to the Iconocast web sites

Virtual tour of Southern California

 

Recent News and Articles on the Keywords: related macular + lucentis + vision  Related to the article below (Last Update: 8/5/2008)

? Macular Degeneration Clinical Trial
WHOI, IL -
In addition, one-third of patients experienced an improvement in their vision after 12 months of treatment. While Lucentis provides hope for patients with ...
Retina Group of New York To Present Seminar on Age-Related Macular ...
MarketWatch - Jul 25, 2008
As people live longer, they are subject to increasing incidence of age-related macular degeneration. Seniors may be unaware that they are at risk for vision ...
Study Looking At Treatment Of Macular Degeneration
KDKA, PA - Aug 1, 2008
... age-related macular degeneration. A critical part of his retina, called the macula, was deteriorating. "It's that provides the fine vision for driving, ...

Calgary Herald
Costly drug poses dilemma
Calgary Herald,  Canada - Jul 28, 2008
Earlier this month, physicians treated Pyke with a new drug -- Lucentis -- that has had remarkable success in combating the effects of wet macular ...
Easy to see proper policy
Calgary Herald,  Canada - Jul 31, 2008
... should not hesitate to fund an expensive drug called Lucentis that has shown dramatic success in treating age-related wet macular degeneration. ...
Regeneron Reports Second Quarter 2008 Financial and Operating Results
MarketWatch - Jul 31, 2008
Regeneron and Bayer HealthCare initiated a Phase 3 global development program of VEGF Trap-Eye in the neovascular form of Age-related Macular Degeneration ...REGN

Daily Mail
New test to identify those vulnerable to AMD - the UK's most ...
Daily Mail, UK - Jul 25, 2008
Age-related macular degeneration (AMD) affects 250000 people in the UK. It damages the central part of the retina and leaves one in 10 sufferers blind. ...
Test to predict most common cause of blindness in elderly ... Telegraph.co.uk
all 6 news articles »
New treatments for macular degeneration
Casa Grande Valley Newspapers, AZ - Jul 16, 2008
Ramona had age-related macular degeneration, a disease that gradually destroys a person's central vision. Rarely presenting itself before age 50, ...
Sight saving treatment denied
Stourbridge News,  UK - Jul 30, 2008
Anneliese Cheslin from Old Swinford suffers from dry and wet Age Related Macular Degeneration, an eye condition which results in the loss of vision and can ...
Real hope for people with severe vision loss;
Sudbury Star, Canada - Jul 12, 2008
Andy was diagnosed with a disease that attacks the central vision of the eye known as wet age-related macular degeneration (AMD); a disease that affects ...
Source: Google News

[PDF] … findings after an intravitreal injection of bevacizumab for neovascular age-related macular … -
PJ Rosenfeld, AA Moshfeghi, CA Puliafito - Ophthalmic Surg Lasers Imaging, 2005 - bmgnri.com
... for neovascularization in age-related macular degeneration (AMD ... patient treated with
pegaptanib still lost vision. 3 Ranibizumab (Lucentis; Genentech Inc., San ...
-

Intravitreal Bevacizumab (Avastin) for Neovascular Age-Related Macular Degeneration -
RL Avery, DJ Pieramici, MD Rabena, AA Castellarin, … - Ophthalmology, 2006 - Elsevier
... the initial injection, left eye vision was 20 ... phase III study of ranibizumab (Lucentis)
for minimally ... or occult neovascular age-related macular degeneration. ...

… -TERM SAFETY AND EFFICACY OF INTRAVITREAL BEVACIZUMAB (AVASTIN) FOR NEOVASCULAR AGE-RELATED MACULAR … -
RM RICH, PJ ROSENFELD, CA PULIAFITO, SR DUBOVY, JL … - RETINA, 2006 - retinajournal.com
... 9. Phase III study shows Lucentis improved vision in patients with wet
age-related macular degeneration. 2005. Available at: http ...

… Efficacy of Multiple Escalating Doses of Ranibizumab (Lucentis) for Neovascular Age-Related Macular … -
PJ Rosenfeld, JS Heier, G Hantsbarger, N Shams - Ophthalmology, 2006 - Elsevier
... is the major cause of severe vision loss in patients with age-related macular
degeneration (AMD). ... to pegaptanib sodium, ranibizumab (Lucentis, Genentech, Inc ...

Ranibizumab for Neovascular Age-Related Macular Degeneration -
PJ Rosenfeld, DM Brown, JS Heier, DS Boyer, PK … - New England Journal of Medicine, 2006 - content.nejm.org
... through the second year, whereas vision in patients in ... escalating doses of ranibizumab
(Lucentis) for neovascular age-related macular degeneration. ...

Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration Twenty-Four … -
AA Moshfeghi, PJ Rosenfeld, CA Puliafito, S … - Ophthalmology, 2006 - Elsevier
... treatment of neovascular age-related macular degeneration (AMD ... drug known as ranibizumab
(Lucentis; Genentech, Inc ... showed a significant vision improvement among ...

Ranibizumab versus Verteporfin for Neovascular Age-Related Macular Degeneration -
DM Brown, PK Kaiser, M Michels, G Soubrane, JS … - New England Journal of Medicine, 2006 - content.nejm.org
... Choroidal Neovascularization in Age-Related Macular Degeneration (ANCHOR ... 0.5 mg of
ranibizumab (Lucentis, Genentech) plus ... Snellen equivalent of 20/125 vision). ...

INTRAVITREAL BEVACIZUMAB TREATMENT OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO AGE-RELATED MACULAR … -
RF SPAIDE, K LAUD, HF FINE, JM KLANCNIK JR, CB … - RETINA, 2006 - retinajournal.com
... treat CNV secondary to age-related macular degeneration (AMD ... 3-line loss of vision)
specifically among ... recent studies using ranibizumab (Lucentis, Genentech; a ...

… Variable Dosing Regimen with Intravitreal Ranibizumab (Lucentis) for Neovascular Age-related Macular … -
AE Fung, GA Lalwani, PJ Rosenfeld, SR Dubovy, S … - American Journal of Ophthalmology, 2007 - Elsevier
... intravitreal injection of ranibizumab (LUCENTIS, Genentech, Inc ... Vision loss (=5
letters) associated with ... AMD = age-related macular degeneration; OCT = optical ...

Systemic Bevacizumab (Avastin) Therapy for Neovascular Age-Related Macular Degeneration Twelve-Week … -
S Michels, PJ Rosenfeld, CA Puliafito, EN Marcus, … - Ophthalmology, 2005 - Elsevier
... anti-VEGF drug known as ranibizumab (Lucentis, Genentech, Inc ... as defined by documented
vision loss (>1 ... AMD = age-related macular degeneration; CNV = choroidal ...

Source: Google Scholar
 
 

Wet age-related macular degeneration, Lucentis improves vision

 
 
A Phase III clinical trial of the drug Ranibizumab ( Lucentis ) met its primary efficacy endpoint of maintaining vision in patients with wet age-related macular degeneration (AMD ).

Approximately 95 percent of patients maintained or improved vision ( defined as a loss of less than 15 letters in visual acuity ) at one year when treated with Lucentis injections compared to approximately 62 percent of those treated in the control arm ( p<0.0001 ).
Patients treated with Lucentis for 12 months had, on average, a significant improvement in visual acuity compared to their visual acuity at study entry, an important secondary endpoint, while the control group demonstrated a substantial decrease in mean visual acuity from baseline to 12 months.

A preliminary analysis of the data showed that adverse events were similar to those seen in earlier trials of Lucentis.
Common side effects occurring in the Lucentis arms more frequently than in the control group were mild to moderate and included conjunctival hemorrhage, eye pain and vitreous floaters.
Serious ocular adverse events occurring more frequently in Lucentis-treated patients were rare ( <1% ) and included uveitis and endophthalmitis.
There appeared to be no imbalance in serious non-ocular adverse events.

Lucentis is a humanized antibody fragment developed at Genentech and designed to bind and inhibit Vascular Endothelial Growth Factor A ( VEGF-A ), a protein that is believed to play a critical role in angiogenesis.

MARINA is a Phase III study of 716 patients in the United States with minimally classic or occult wet AMD who were randomized 2:1 to receive intravitreal Lucentis injections or a control regimen.
The control regimen consisted of a sham injection, meaning the treating physician prepares and anesthetizes the patient’s eye but does not perform an injection.
Patients treated with Lucentis were further randomized to receive either a 0.3 mg or 0.5 mg dose of Lucentis once a month for two years.

Exclusion criteria included prior subfoveal laser treatment, Verteporfin photodynamic therapy ( PDT ) or experimental treatments for wet AMD.
Visual acuity was measured using the Early Treatment of Diabetic Retinopathy ( ETDRS ) chart, the standard method of quantifying visual acuity.

Age-related macular degeneration ( AMD ) is a major cause of painless central visual loss and is the leading cause of blindness for people over the age of 60.
The National Eye Institute estimates that there are 1.6 million people with AMD in the United States alone and that this prevalence will grow to 2.95 million by 2020.
AMD occurs in two forms: dry and wet.
The dry form is associated with atrophic cell death of the central retina or macula, which is required for fine vision used for activities such as reading, driving or recognizing faces.
The wet form is caused by growth of abnormal blood vessels also known as choroidal neovascularization ( CNV ) or ocular angiogenesis under the macula.
These vessels leak fluid and blood and cause scar tissue that destroys the central retina. This results in a deterioration of sight over a period of months to years.

Source: Genentech, 2005
 
 
 
Google
Web www.iconocast.com
 
 
 

 

Continue News With: News7 ; News8 ; News9 ; News9A


ADVERTISEMENT

Iconocast is about learning and teaching without borders; we offer eMarketing, Internet Advertising, Internet Marketing, Search Engine Optimization, Search Engine Marketing, Online Branding, and eMarketing News Services. Home

 © 2002-2006

Keywords::

Contact Iconocast

Home Page